RecruitingCirrhosis, LiverLiver FibrosisAscites Hepatic
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
Eligible age
18–75 yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the maximum tolerated dose or optimal beneficial dose in patients with Child Pugh A and B Cirrhosis.
Sponsor: PharmaIN
Where it's recruiting
Arizona
Chandler
California
Coronado
Louisiana
Marrero
Minnesota
Rochester
Ohio
Cleveland
Pennsylvania
Philadelphia
Texas
Dallas · San Antonio
Source: ClinicalTrials.gov · NCT05490888 · last updated 2025-09-05